仲間みたいな顔してこっち来んな｜SBG急落と「半導体株」の落とし穴｜2026.10.20
Same AI Theme. Different Balance Sheet. Wearing the semiconductor team’s jersey does not give you the same balance sheet. SoftBank Group has genuine semiconductor ex
Same AI Theme. Different Balance Sheet.
Wearing the semiconductor team’s jersey does not give you the same balance sheet. SoftBank Group has genuine semiconductor exposure through Arm. The analytical mistake is assuming that this exposure makes its earnings, financing needs and share-price drivers interchangeable with those of a memory or equipment supplier.
On 20 October 2026, SBG opened 2.31% below its previous close, then lost a further 3.78% from its opening price. The close-to-close decline was 6.01%. The session high, JPY 4,734, was only one yen above the opening price. The low came at 15:03, and the close was approximately 0.71% below final VWAP. These figures describe a weak session, though daily OHLC data cannot show every intraday rebound. [1]
| Measure | SBG · 20 Oct | Kioxia · 19 Oct |
| Previous close → open | −2.31% | −5.01% |
| Open → close | −3.78% | ＋7.04% |
| Previous close → close | −6.01% | ＋1.68% |
| Close vs final session VWAP | −0.71% | ＋1.85% |
This comparison uses different dates to illustrate two price patterns. It is not a same-session relative-performance test or proof of business superiority.
The financing question
Bloomberg reported at 11:07 JST on 20 October that SBG’s five-year CDS spread had reached 432 basis points as of 05:30, roughly a four-year high. Its reporting linked credit concerns to AI investment and possible additional acquisition funding. A CDS spread is a credit-risk pricing measure, not a direct default probability or the company’s actual borrowing interest rate. The article’s publication time is not proof of when market participants first received the underlying information. [2]
Reuters had already reported on 17 October that SBG was considering acquiring Allied Universal, with a possible valuation of about USD 18 billion. Talks were preliminary and no final decision had been reached. This was an existing backdrop, not a newly announced deal on 20 October. That reported valuation is not evidence of the final cash payment or funding structure. [3]
My interpretation: investors may be reassessing the funding required to turn AI ambitions into operating assets. The credit-market evidence supports investigating that explanation. It does not let me assign a specific portion of today’s equity decline to CDS, acquisitions, Arm or other portfolio holdings.
Assets and liabilities can move in opposite directions
SBG’s official NAV framework subtracts net debt from investment holdings. Its published table is based on June 2026 data and is not a live 20 October valuation. It establishes the analytical structure, not today’s leverage or investment attractiveness. [4]
Asset valuations can decline while funding becomes more expensive. This creates a potential two-sided pressure on equity value. Conversely, sound financing terms, stronger investment cash flows or improved asset values could weaken the bearish interpretation. An acquisition funded on attractive terms is not automatically destructive.
A sharp decline is not proof of a volume surge
The supplied session volume was 50,425,000 shares, about 10% below the prior session’s 56,034,400. Execution count was about 82% of the supplied one-year average. Neither supports calling the day an explosion in trading activity. Execution count is not the number of investors, and these measures cannot identify forced selling or institutional liquidation. [1]
What would change the interpretation?
I would watch the next session’s evolving VWAP, whether recoveries hold, and whether credit pricing stabilizes. More consequential evidence would be disclosed financing terms, actual investment commitments, liquidity, maturities and updated asset values. Today’s final VWAP must not be used as if it were available in the morning, or as tomorrow’s VWAP.
TokyoBrainie’s conclusion: Arm makes SBG relevant to semiconductor research. Its investment-company balance sheet makes financing research equally necessary. The team jersey is shared; the economic risks are not identical.
